Wikipedia -WSS

Wikipedia

author：focus 2025-10-01 22:59:01 - browse：72515

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： FDA seeks to regulate lab

WSS

Google says AlphaFold 3 can map a vast universe of biomolecules

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Why do women spend more than men on medical expenses?

CDC wastewater surveillance dashboard to track bird flu hotspots

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Use wet bulb globe temperature, not heat index, to protect workers

focus

Wikipedia

leisure time

Medicare details structure of new drug price negotiation program

Mindstrong's demise and the future of mental health care

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Menendez indictment could see pharma lose a key ally

Jerome Adams on the need for new antivirals for Covid

Brain worms: The science behind RFK Jr.'s parasitic infection

Walensky prepares to leave CDC — and Congress — behind

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

After affirmative action ruling, medical educators look to 'holistic review'

Sanofi strikes deal with Novavax, boosting the vaccine maker

focus

H5N1 bird flu: what we're starting to learn about infection in cows

Would Medicare drug price negotiations stall in a shutdown?

Intercept Pharmaceuticals sells itself for less than $1 billion

H5N1 communication has been strictly for the birds

Study: Adult vaccinations pay for themselves in societal benefits

Address the ethical violations that led to 'Three Identical Strangers'

focus

hotspot

explore

knowledge